Page 41 - IMO-2-3

Innovative Medicines & Omics Tyrosine kinases: Structure, mechanism, and therapeutics

17. Nair S, Bonner JA, Bredel M. EGFR mutations in head and clinical features, pathophysiology and treatment. Front Mol
neck squamous cell carcinoma. Int J Mol Sci. 2022;23(7):3818. Neurosci. 2020;13:159.
doi: 10.3390/ijms23073818 doi: 10.3389/fnmol.2020.00159
18. Vigneri PG, Tirrò E, Pennisi MS, et al. The insulin/IGF 30. Raj S, Kesari KK, Kumar A, et al. Molecular mechanism(s)
system in colorectal cancer development and resistance to of regulation(s) of c-MET/HGF signaling in head and neck
therapy. Front Oncol. 2015;5:230. cancer. Mol Cancer. 2022;21(1):31.
doi: 10.3389/fonc.2015.00230 doi: 10.1186/s12943-022-01503-1
19. Chen PH, Chen X, He X. Platelet-derived growth factors 31. Tsou WI, Nguyen KQ, Calarese DA, et al. Receptor
and their receptors: Structural and functional perspectives. tyrosine kinases, TYRO3, AXL, and MER, demonstrate
Biochim Biophys Acta. 2013;1834(10):2176-2186. distinct patterns and complex regulation of ligand-induced
activation. J Biol Chem. 2014;289(37):25750-25763.
doi: 10.1016/j.bbapap.2012.10.015
20. Tomassetti C, Insinga G, Gimigliano F, Morrione A, doi: 10.1074/jbc.M114.569020
Giordano A, Giurisato E. Insights into CSF-1R expression in the 32. Vázquez-Bellón N, Martínez-Bosch N, García de Frutos P,
tumor microenvironment. Biomedicines. 2024;12(10):2381. Navarro P. Hallmarks of pancreatic cancer: Spotlight on
21. Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic TAM receptors. eBioMedicine. 2024;107:105278.
signaling pathways and anti-angiogenic therapy for cancer. doi: 10.1016/j.ebiom.2024.105278
Signal Transduct Target Ther. 2023;8(1):198.
33. Leppänen VM, Saharinen P, Alitalo K. Structural basis of
doi: 10.1038/s41392-023-01460-1 Tie2 activation and Tie2/Tie1 heterodimerization. Proc Natl
22. Farooq M, Khan AW, Kim MS, Choi S. The role of Acad Sci U S A. 2017;114(17):4376-4381.
fibroblast growth factor (FGF) signaling in tissue repair and doi: 10.1073/pnas.1616166114
regeneration. Cells. 2021;10(11):3242.
34. Liang LY, Patel O, Janes PW, Murphy JM, Lucet IS. Eph
doi: 10.3390/cells10113242 receptor signalling: From catalytic to non-catalytic
23. Berger H, Wodarz A, Borchers A. PTK7 Faces the Wnt in functions. Oncogene. 2019;38(39):6567-6584.
development and disease. Front Cell Dev Biol. 2017;5:31. doi: 10.1038/s41388-019-0931-2
doi: 10.3389/fcell.2017.00031 35. Mahato AK, Sidorova YA. RET receptor tyrosine kinase:
24. Ji J, Qian Q, Cheng W, et al. FOXP4-mediated induction of Role in neurodegeneration, obesity, and cancer. Int J Mol Sci.
PTK7 activates the Wnt/β-catenin pathway and promotes 2020;21(19):7108.
ovarian cancer development. Cell Death Dis. 2024;15(5):332. doi: 10.3390/ijms21197108
doi: 10.1038/s41419-024-06713-7 36. Shi F, Mendrola JM, Sheetz JB, et al. ROR and RYK
25. Hechtman JF. NTRK insights: Best practices for pathologists. extracellular region structures suggest that receptor tyrosine
Modern Pathol. 2022;35(3):298-305. kinases have distinct WNT-recognition modes. Cell
Rep. 2021;37(3):109834.
doi: 10.1038/s41379-021-00913-8
doi: 10.1016/j.celrep.2021.109834
26. Belliveau DJ, Krivko I, Kohn J, et al. NGF and
neurotrophin-3 both activate TrkA on sympathetic neurons 37. Chen L, Kong X, Fang Y, et al. Recent advances in the role of
but differentially regulate survival and neuritogenesis. J Cell discoidin domain receptor tyrosine kinase 1 and discoidin
Biol. 1997;136(2):375-388. domain receptor tyrosine kinase 2 in breast and ovarian
cancer. Front Cell Dev Biol. 2021;9:747314.
doi: 10.1083/jcb.136.2.375
doi: 10.3389/fcell.2021.747314
27. Menck K, Heinrichs S, Baden C, Bleckmann A. The WNT/
ROR pathway in cancer: From signaling to therapeutic 38. Shenoy GP, Pal R, Purwarga Matada GS, Singh E,
intervention. Cells. 2021;10(1):142. Raghavendra NM, Dhiwar PS. Discoidin domain receptor
inhibitors as anticancer agents: A systematic review on
doi: 10.3390/cells10010142 recent development of DDRs inhibitors, their resistance
28. Song P, Gao Z, Bao Y, et al. Wnt/β-catenin signaling pathway and structure activity relationship. Bioorg Chem.
in carcinogenesis and cancer therapy. J Hematol Oncol. 2023;130:106215.
2024;17(1):46. doi: 10.1016/j.bioorg.2022.106215
doi: 10.1186/s13045-024-01563-4
39. Ditsiou A, Gagliano T, Samuels M, Vella V, Tolias C,
29. Cao M, Koneczny I, Vincent A. Myasthenia gravis with Giamas G. The multifaceted role of lemur tyrosine kinase 3
antibodies against muscle specific kinase: An update on in health and disease. Open Biol. 2021;11(9):210218.

Volume 2 Issue 3 (2025) 35 doi: 10.36922/IMO025200022